文献速递消化系统肿瘤

瑞戈非尼治疗转移性结直肠癌的真实世界CORRELATE研究

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
PubMed 文献 · Eur J Cancer · 2019-11-04

CORRELATE是一项国际前瞻性观察研究,纳入1037例既往接受过获批治疗的转移性结直肠癌患者,由医生按当地获批标签决定使用瑞戈非尼。主要终点为安全性,结果显示毒性谱与III期试验相似,中位OS为7.7个月,中位PFS为2.9个月。

要点

  • 真实世界中瑞戈非尼毒性谱与III期试验相似,最常见的III/IV级药物相关TEAE为疲乏(9%)、手足皮肤反应(7%)和高血压(6%)。
  • 药物相关V级(致死性)TEAE发生率为1%,24%的患者因药物相关TEAE进行剂量下调。
  • 中位OS为7.7个月(95%CI 7.2-8.3),中位PFS为2.9个月(95%CI 2.8-3.0)。

核心结论

  • 在真实世界转移性结直肠癌患者中,瑞戈非尼的毒性谱与III期试验报告相似。
  • 近半数患者起始剂量低于获批的160 mg剂量,中位OS和PFS处于III期试验观察到的范围内。

研究设计与样本

  • 国际、前瞻性、观察性CORRELATE研究,纳入1037例既往接受过获批治疗的转移性结直肠癌患者。
  • 由治疗医生根据当地卫生当局获批标签决定是否使用瑞戈非尼。
  • 主要目标为安全性,采用NCI CTCAE v4.03评估治疗中出现的不良事件(TEAE)。

主要发现

  • 中位年龄65岁(范围24-93),87%患者ECOG体能状态为0-1。
  • 56%患者有KRAS突变,7%有NRAS突变,4%有BRAF突变。
  • 57%患者初始瑞戈非尼剂量为160 mg/日。
  • 最常见的III或IV级药物相关TEAE为疲乏(9%)、手足皮肤反应(7%)和高血压(6%)。
  • 药物相关V级(致死性)TEAE发生于1%患者,24%患者因药物相关TEAE进行剂量下调。

临床怎么用

  • 真实世界中使用瑞戈非尼需关注疲乏、手足皮肤反应和高血压等常见III/IV级毒性,并依据TEAE进行剂量调整。
  • 近半数患者起始剂量低于160 mg/日,临床可根据患者状况个体化选择起始剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regorafenib prolonged overall survival (OS) versus placebo in patients with treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an observational study of regorafenib for patients with mCRC in real-world clinical practice. METHODS: The international, prospective, CORRELATE study recruited patients with mCRC previously treated with approved therapies, for whom the decision to treat with regorafenib was made by the treating physician according to the local health authority approved label. The primary objective was safety, assessed by treatment-emergent adverse events (TEAEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03). RESULTS: A total of 1037 patients were treated. The median age was 65 years (range: 24-93); 87% of patients had Eastern Cooperative Oncology Group performance status 0-1, 56% of patients had KRAS, 7% had NRAS and 4% had BRAF mutations. The initial regorafenib dose was 160 mg/day in 57% of patients. The most common grade III or IV drug-related TEAEs were fatigue (9%), hand-foot skin reaction (7%) and hypertension (6%). Drug-related grade V (fatal) TEAEs occurred in 1% of patients. Dose reductions for drug-related TEAEs occurred in 24% of patients. Median OS was 7.7 months (95% confidence interval [CI]: 7.2-8.3), and median progression-free survival (PFS) was 2.9 months (95% CI: 2.8-3.0). CONCLUSIONS: In this real-world, observational study of patients with mCRC, the regorafenib toxicity profile was similar to that reported in phase III trials. The starting dose for almost half of patients was less than the approved 160-mg dose, and the median OS and PFS were in the range observed in phase III trials. TRIAL REGISTRATION: NCT02042144.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ducreux M, Petersen LN, Öhler L, et al. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Eur J Cancer. 2019. PMID: 31698328. doi:10.1016/j.ejca.2019.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。